+

WO1999020649A1 - Peptides espaceurs et membranes contenant ces peptides - Google Patents

Peptides espaceurs et membranes contenant ces peptides Download PDF

Info

Publication number
WO1999020649A1
WO1999020649A1 PCT/EP1998/006344 EP9806344W WO9920649A1 WO 1999020649 A1 WO1999020649 A1 WO 1999020649A1 EP 9806344 W EP9806344 W EP 9806344W WO 9920649 A1 WO9920649 A1 WO 9920649A1
Authority
WO
WIPO (PCT)
Prior art keywords
ser
ala
group
peptide
xaa
Prior art date
Application number
PCT/EP1998/006344
Other languages
German (de)
English (en)
Inventor
Renate Naumann
Alfred Jonczyk
Eva-Kathrin Schmidt
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Priority to JP2000516989A priority Critical patent/JP2001520236A/ja
Priority to EP98954352A priority patent/EP1025118A1/fr
Publication of WO1999020649A1 publication Critical patent/WO1999020649A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Definitions

  • the present invention relates to lipid membranes attached to a solid support via thiopeptides as linker or spacer molecules.
  • These lipid bilayer can incorporate a plurality of membrane proteins such as ion channels, ionophores and integral membrane proteins such as ion pumps and receptors and can be used in biosensing devices, when the ion flux is modulated by agonists, antagonists, drugs, substrates and ligands.
  • membrane proteins such as ion channels, ionophores and integral membrane proteins such as ion pumps and receptors.
  • Such a system is useful as a screening test for pharmaceutically active compounds.
  • Polymeric spacers have been used to prepare such films, particularly polyoxiethylene spacers (US 5,401 ,378 or WO 92/17 788) also attached to the gold support via Au-S-groups. These spacers are, however, not designed to form secondary structures such as helices and therefore, they are less rigid and more ready to collapse compared to peptides. (Layer thicknesses are not reported) Lipid films with polyoxiethylene spacers, therefore, were shown to incorporate ion channels and ionophores such as alamethicin, gramicidin and valinomycin. Ion transport through these channels was measured by impedance spectroscopy.
  • membrane spanning proteins with large domains extending in the aqueous phase such as receptors and ion pumps were incorporated only rarely and not preserving the activity of these proteins.
  • Peptide spacers tethered to the gold support via -S-S- or -S-H groups are disclosed in WO 96/18 645 and DE 44 44 893.7. They were shown to be covalently linked in situ to a lipid (DMPE) to form peptide spacered lipid monolayers. These monolayers in contact to a lipid vesicle suspension spontaneously formed peptide supported lipid bilayers.
  • DMPE lipid
  • One way to incorporate membrane proteins had been shown to be the fusion of vesicles containing the reconstituted protein, whereby their activity was being preserved.
  • the peptide spacer had therefore proved to be compatible with the integral protein. Because of the poor solubility of the thiopeptide disclosed in WO 96/18 645 and DE 44 44 893.7 the synthesis of the thiopeptide-lipid adduct in the bulk was not possible. It had therefore been carried out in-situ on the gold support. The electrical properties of the system were also not satisfying. In order to remove these shortcomings the system has to be improved with respect to: - the peptide sequence;
  • the invention is based on the object of finding novel compounds with improved properties, in particular those which can be used to prepare peptide layers, peptide-analogous layers, peptide-lipid layers or cell membranes or devices containing such membranes.
  • the present invention relates to Ijpid membranes attached to a solid support via thiopeptides as linker or spacer molecules.
  • these films are formed from a thiopeptide described below which is covalently attached on one side to the gold support via Au-S- bonds and on the other to a phospholipid (DMPE) via CO-NH-bonds, thus forming a thiopeptide-lipid monolayer.
  • DMPE phospholipid
  • CO-NH-bonds CO-NH-bonds
  • these supported lipid bilayers are interesting as model systems for biological membranes. They are particularly useful when membrane spanning proteins are incorporated in the lipid film. Then they can be used as biosensors or systems for bioassays when the ion flux is modulated by agonists, antagonists, drugs, substrates and ligands.
  • the binding properties of the membrane proteins for example towards antibodies and ligands, can be assayed simultaneously together with the ion flux. Unspecific binding is reduced due to the lipid environment.
  • Such a system could be used as a screening test for pharmaceutically active compounds.
  • the invention relates to peptides or peptide-analogous compounds of the formula I
  • X is a diamino acid, which can be acylated once or twice by an acyl moiety with 1 to 22 C-atoms or a sulphur containing residue like a 1 ,2-Dithiolane-3-pentanoyl
  • a N is a single bond or
  • Xaa 1 Xaa 1 Pro B is ⁇ aa 2 Xaa 1 Xaa 1 Xaa 2 Xaa 2 Xaa 1 Xaa 2
  • a c is a single bond
  • Y is a sulphur containing residue like Cys, the carboxyl group of which optionally can be substituted by -OAlk, -NH 2 , -NHAlk or -
  • the side chain amino group of these diamino acids can be acylated by an acyl moiety with 2 to 22 C-atoms; or a dipeptide containing two diamino acids like Lys, Orn, Dpr, or Dbu, optionally one or both side chain amino groups of these diamino acids can be acylated by an acyl moiety with 2 to 22 C- atoms or
  • Alk and Alk ' are independent of each other a straight chain or branched alkyl with 1 to 11 C-atoms, Pro can also be 3Hyp, or 4Hyp; Xaa 1 is a hydroxy amino carbonic acid with 3 or 4 C-atoms, e.g. Ser,
  • Xaa 2 is a 2-alkylglycine with C, - C 5 alkyl (straight chain or branched), e.g. Ala, Abu, Val, lie, or Leu; wherein either X or Y contain at least one sulphur atom, and wherein only of residue A N or A c may represent a single bond.
  • group X contains at least one sulphur atom, e.g. group X represents a Lip group or a group like HS-(CH 2 ) 2 -CO-; groups A N and L N both represent single bonds; group A c represents Pro Xaa 1 Xaa 1 group L c represents a single bond or an oligomer (number of monomers between 2 and 4) of an medium chain ⁇ -amino acid like 6- aminocaproic acid; group Y represents Lys(Myr)-Lys(Myr), where Myr represents a myristoyl residue bound to the side chain amino group of Lys.
  • group X contains at least one sulphur atom, e.g. group X represents a Lip group or a group like HS-(CH 2 ) 2 -CO-; groups A N and L N both represent single bonds; group A c represents Pro Xaa 1 Xaa 1 group L c represents a single bond or an oligomer (number of monomers
  • group X represents Myr-Lys(Myr), where Myr represent myristoyl residues bound to the amino groups of Lys;
  • group L N represents a single bond or an oligomer (number of monomers between 2 and 4) of an medium chain ⁇ -amino acid like 6- aminocaproic acid;
  • groups A N represents Pro Xaa 1 Xaa 1 groups A c and L c both represent single bonds;
  • group Y contains at least one sulphur atom, e.g. group Y represents
  • Lys can be replaced by other diamino acids as mentioned above and Myr can be replaced by other acyl moieties containing 2 to 22 C-atoms, like those mentioned later in this disclosure.
  • a first terminal group containing sulphur is used to anchor the peptide to the noble metal surface.
  • the core spacer B creates a self-organizing domain, the intermediate groups A c and/or A N cause the whole structure to be flexible.
  • the other terminal group is lipophilic and inserts into the membrane structure. This structure allows to create stable membrane structures covalently bound to a noble metal surface.
  • the alternatives mentioned above are a result of the polarity of the peptide bond.
  • the invention furthermore relates to processes for the production of the peptides of formula I, and to peptide layers covalently bonded via sulphur bridges of one of the terminal groups to a noble metal surface, as well as to synthetic cell membranes and complexes containing a membrane protein in said synthetic cell membrane.
  • the invention furtermore relates to biosensing devices containing such complexes and their use for receptor binding assays and investigating the activity of pharmaceutical and crop protection agents.
  • the invention furthermore relates to the formation by self assembly of stable thiopeptide-lipid monolayers on top of the noble metal surface which can be stored for a longer period of time, for example in the form of an electronic chip and which can be used at any time to form the respective lipid bilayers either by fusion with liposomes or by adding a lipid solution in a non-aqueous solution which is then diluted with an aqueous buffer.
  • the lipid bilayer can be stored ready to use in an aqueous environment, possibly stabilized by trehalose or glycerin present in the solution.
  • the preferred embodiment of such a device would be a multi-electrode chip or chip array, each electrode individually addressable, the signal of which can be monitored sequentially or by a multiplexer.
  • the chip would contain a number of gold electrodes, each of them surrounded by a teflon sheet, preferably using a teflon mask.
  • the purpose of the teflon sheet would be to provide a lipid reservoir and at the same time to contain the aqueous solution limiting and stabilizing the lipid bilayer.
  • Fig. 1 depicts schematically the forming of bilayers by reacting the lipid monolayer, which is bound via a thio peptide to the noble metal substrate (e.g. gold), with liposomes.
  • Fig. 2 depicts an electrochemical cell, and Fig. 3 a cell, which allows both electrochemical and optical measurements.
  • Fig. 4 to 6 show SPS spectra for the formation of lipid mono- and bilayers as well as the insertion of cytochrome c oxidase and the acetylcholine receptor is given in figs.4 and 5 respectively.
  • cytochrome c For the binding of cytochrome c to cytochrome c oxidase, see fig.6.
  • Fig. 7 depicts schematically a measuring device for surface plasmon fluorescence spectroscopy (SPFS); fig. 8, 9, and 11 show the results of such measurements.
  • SPFS surface plasmon fluorescence spectroscopy
  • Fig. 10 depicts schematically the use of primary and secondary antibodies. Details are given below and in the examples.
  • Lipids and proteins are major components of biological membranes.
  • Lipid bilayers are regarded as a model of cell membranes. Peptides or proteins can be incorporated into such lipid bilayers so that they extend through them by insertion perpendicular to the surface (J.C. Huschilt et al. BBA 979, 139-141 (1989)).
  • the conformation of the protein-bilayer assembly is partly determined by the sequence of the peptide, for example the incorporation of membrane proteins depends on the surface charge of the peptide.
  • Peptides useful as spacers in membranes are disclosed along with additional technical background in WO 96/18 645 and DE 44 44 893.7.
  • the lipid component of the membranes as disclosed in WO 96/18 645 and DE 44 44 893.7 is typically bound via an ester linkage of the C- terminal amino acid.
  • the lipid component of the present invention can be integrated into the amino acid sequence by using
  • a further preferred embodiment would be a multi-electrode chip ready to form the lipid bilayer-protein assembly by fusion with liposomes or alternatively with a preformed lipid bilayer into which a membrane protein can be inserted by adding it in the solubilized form which is then diluted below the critical micelle concentration (cmc).
  • cmc critical micelle concentration
  • a further preferred embodiment would be such a bilayer-protein assembly with several interacting proteins including ion channels.
  • the embodiments described above can be used as biosensor devices since they respond in a reversible fashion to substrates of the membrane proteins incorporated. Alternatively, they can be used as a screening test for pharmaceutically active compounds.
  • Membrane proteins according to the present invention and different from conventional screening tests on a microtiter plate, are placed in an environment matching very much natural conditions. They are thus kept in the active state. Binding effects can be studied much more specifically and moreover in real time. The effect of agonists and antagonists on electrical and/or optical properties can be investigated simultaneously.
  • gold as electrically conducting material for electrodes.
  • other noble metals like platinum, silver, or palladium or semi-noble metals like copper, as well as alloys containing such noble or semi-noble metals can be used for the same purpose. Therefore mentioning gold as material for electrodes is to be understood as example, not as an limitation.
  • the expression noble metals used in this disclosure is to be understood to comprise the nobel metals, as well as semi-nobel metals and alloys containing nobel metals and/or semi-nobel metals.
  • mercaptoalkylcarboxy-peptides of the formula I can be bound to gold surfaces and that they organize themselves to dense layers, with improved characteristics, particularly after using the improved preparation procedure described below.
  • Lipids for example dimyristoyl- phosphatidyloxyethyiamine, DMPE
  • DMPE dimyristoyl- phosphatidyloxyethyiamine
  • Lipids or lipophilic residues can be covalently coupled ex-situ before the peptide is bound to the gold surface. This allows a simplified procedure for preparing the tethered lipid membranes.
  • lipid layers can also be applied to the peptide layer by the Langmuir-Blodgett technique.
  • the method is described, for example, by G. Puu, I. Gustavson, P. -A. Ohlsson, G. Olofson and A. Sellstr ⁇ m in Progress in Membrane Biotechnologie page 279 et seq. (1991 ), Birkhauser Verlag, Basel (Eds. Femande ⁇ Chapman/Packer).
  • the peptide spacer serves to form a hydrophilic layer between the hydro- phobic lipid layer and the gold electrode.
  • the additional flexible portion improves the stability of the lipid layer.
  • the lipid monolayer formed in this way can be provided with a second lipid layer, for example with the aid of the Langmuir-Blodgett technique, by fusion of liposomes or diluting a lipid solution in a non-aqeous solvent (painted membranes), to result in defined lipid bilayers which represent a model of a biological membrane to the extent that they are adjacent to an aqueous phase on both sides.
  • the aqueous phase adjacent to the electrode is represented by the peptide layer. It is shown to have a layer thickness corresponding to molecular dimensions of the helical conformation (N. Bunjes et al., Langmuir (1997)).
  • lipid bilayers thus formed are shown to insert membrane proteins such as HATPase, NaKATPase, cytochrome c oxidase, and acetylcholine receptor and thus permit their electrical, structural and binding properties to be investigated.
  • lipid-peptide-gold constructs are accordingly capable of forming bilayers and inserting proteins.
  • the formation and the arrangement (order state) of the layers can be measured by cyclovoltametry, impedance spectroscopy and surface plasmon resonance spectroscopy (SPS).
  • SPS surface plasmon resonance spectroscopy
  • the binding process of antibodies, ligands, agonists, antagonists, substrates, drugs etc. to the incorporated membrane proteins can be measured in real time by SPS and more effectively by surface plasmon fluorescence spectroscopy (SPFS), and fluorescence spectroscopy. Binding constants and kinetic data can be obtained from these measurements by known procedures.
  • electrical properties of the ion flux through the proteins such as ion channels, receptors and ion pumps can be monitored by impedance spectroscopy (IS). Direct electron exchange between protein and electrode can be measured by other electrochemical techniques.
  • SPR is known and used for biosensors (e.g. EP 0442 922).
  • Plasmon surface polaritons (surface plasmons for short) are excited along the metal-dielectric interface. Their field amplitudes decay exponentially, both along the interface and into the dielectricum, with the maximum intensity being at the interface.
  • a Kretschmann set-up is used for this configuration.
  • the refractive index of the prism np and the angle of incidence define the x-component of the momentum of the exciting photon, where in the SPS experiment the angle of incidence is varied and the reflected intensity is detected by a photodiode.
  • a thin dielectric coating of the metal film e.g., a supported membrane shifts the angle of resonant coupling to surface plasmon modes to higher angles.
  • This angular shift depends on the thickness d of the layer and its optical properties relative to the surrounding medium, i.e., on the difference between their respective indices of refraction.
  • Examples of SPS spectra for the formation of lipid mono- and bilayers as well as the insertion of cytochrome c oxidase and the acetylcholine receptor is given in figs.4 and 5 respectively.
  • Plasmon surface polaritons or surface plasmons are transverse electro-magnetic waves that propagate along a metal-dielectric interface, their field amplitudes decaying exponentially perpendicular to the interface thus allowing to introduce a surface sensitive probing technique.
  • the metal acts as an oscillator that can be driven by an electromagnetic wave impinging upon that interface (Kretschmann configuration Fig. 7). Therefore onre is dealing with the resonant excitation of a coupled state between plasma oscillations and the photons, that is, "plasmon surface polaritons". This resonance phenomenon can be clearly seen in the attenuated total reflection (Fig.
  • a resonant electro magnetic field enhancement located at the metal-dielectric interface.
  • a resonant amplification of the electromagnetic field takes place.
  • the intensity of this surface located field can oversize the incident intensity by a factor of 10 (gold) to 100 (silver).
  • This intensity enhancement can be employed to increase the fluorescence emission of surface bound dye molecules excited by this amplified electro- magnetic field.
  • a spacer between the dye molecule and the metal is required providing a spatial separation of at least 5-10 nm.
  • the experimental detection equipment shown in Fig 7 allows to monitor reflectivity and fluorescence simultaneously.
  • a HeNe Laser in the Kretschmann configuration is employed to excite the surface plasmons at the metal-dielectric interface.
  • the selected laser provides the matching condition for the excitation wavelength of the selected dye molecule (CY5) yielding to the surface plasmon enhanced fluorescence emission.
  • the temperature controlled sample is mounted on a rotary table in a theta/2 theta configuration.
  • the reflectivity is detected by a photo diode and monitored by a lock in amplifier.
  • the emitted fluorescence blocked by an interference filter is measured by a photo multiplier in photon counting mode mounted at the back side of the sample.
  • a confer is employed to digitize the photo multiplier signal output.
  • the experimental setup is driven by a PC allowing the real time simultaneous detection of reflectivity and fluorescence.
  • FIG. 2 An similar version of an electrochemical cell is drawn in figure 2. It comprises a Plexiglas body (1), the sample compartment (2) is lined with a teflon spacer (3) additionally provided with a sealing lip limiting the area of the gold support (4), which is used as working electrode; the gold support carries the membrane into which optionally a membrane protein can be integrated; a removable thermostated chamber beneath the support (not shown), a platinum counter electrode (5) and Ag/AgCI, saturated KCl reference electrode (6).
  • the cell is equipped with a fiber optic bundle (7), and with a inlet (8) and outlet (9) in order to fill and empty the cell.
  • the teflon spacer is removed and impregnated with 10 ⁇ l of a 0.5% solution of egg phosphatidyl choline in hexane prior to each measurement. Then the gold support is attached to the spacer as well as to the gold contact via the thermostated chamber. Typically the volume of the assembled cell is 800 ⁇ l.
  • a further improved cell which allows to measure SPS/SPFS/IS simultaneously is depicted in fig. 3:
  • the body of the cell (11 ) is made from teflon.
  • a sealing lip (12) limits the area of the gold support (13), which is used as working electrode; the gold support carries the membrane into which optionally a membrane protein can be integrated. Typically the diameter of the sealing lip is 4 mm.
  • the inner part of the chamber (14) is formed as a conus from 4-20 mm diameter.
  • a removable glass slide (15) covers the backside of the chamber.
  • a thermostated chamber can be added (not shown).
  • a platinum counter electrode and Ag/AgCI, saturated KCl reference electrode are inserted in the chamber via two tubes (16) and (17).
  • FIG. 7 A schematic view of a measuring device for measuring SPFS is depicted in Fig. 7. Compared to SPS-measurements the SPFS-measurement improves the sensitivity. Sensitivity can be further improved by using a second antibody labeled with a fluorochrome.
  • a schematic view of a membrane protein labeled with a first antibody, to which in turn a second antibody is bound is depicted in Fig. 9. The second antibody is labeled with a fluorochrome.
  • the compounds of the formula I can be employed as building blocks for synthetic peptide layers or biological membranes, in particular cell membranes. They can be bound to a nobel metal support.
  • membrane proteins can be integrated by processes known in the art.
  • the resulting complex of tethered membrane and membrane protein can be used in a biosensing device for measuring analytes (biosensor) and for measuring interactions of the membrane proteins with reactants in solution such as a bioassay for a drug screening test.
  • membrane proteins which can be integrated into membranes are: Cytochrome c oxidase (COX), ATPases from different sources (e.g.
  • integrins like e.g. Integrin ⁇ v ⁇ m.
  • Other membrane proteins are known in the art. These complexes can be used in devices for measuring specific binding assays for antibodies and for other electrochemical and optical measurements in order to quantify biological interactions.
  • Xaa 1 hydroxy am ⁇ carbonic acid with 3 or 4 C-atoms e.g. Ser, Thr, allo-Threonine, homo-Serine.
  • Xaa 2 2-alkylglycine wherein the alkyl group contains 1 to 5 C-atoms and can be straight or branched, e.g. Ala, Abu, Val, He, or Leu
  • alkyl Ci to Cn alkyl or alkylene (straight chain or branched)
  • Trt trityl (triphenylmethyl).
  • the ⁇ -amino acid moieties which form the portions L N respectively L c contain 3 to 0 carbon atoms; examples for suitable ⁇ -amino acids are ⁇ - alanine, 4-aminobutyric acid, and 6-aminocaproic acid.
  • acyl residues with with 2 to 22 C-Atomes are: acetyl, propanoyi, butyryl, caproyi, preferred embodiments of these acyl residues are myristoyl, lauroyl, palmitoyi, and stearoyi, as well as their unsaturated counterparts.
  • amino acids or residues thereof are able to occur in several enantiomeric forms, all these forms and also their mixtures (for example the DL forms) are included hereinbefore and hereinafter, for example as constituent of compounds of the formula I. It is furthermore possible for the amino acids or the amino acid residues to be derivatized in a form known per se.
  • the invention furthermore relates to a process for preparing a compound of the formula I or one of its salts, whereby it is liberated from one of its functional derivatives by treatment with a solvolyzing or hydrogenolyzing agent.
  • a solvolyzing or hydrogenolyzing agent can be obtained in analogous manner as disclosed in WO 96/18 645 and DE 44 44 893.7.
  • X is containing sulphur it is preferably Trt-S-alkyl-CO, HS-alkyl-CO-, Trt- S-alkyl-CO-NH-alkyl'-CO-, HS-alkyl-CO-NH-alkyl'-CO-, 1 ,2-Dithiolane-3- pentanoyl- (lipoyl-), N-acetyl cysteine, or N-acetyl homocysteine.
  • alkyl and alkyl' are, independently of one another, preferably -CH 2 -, -(CH 2 ) 2 -, -(CH 2 ) 3 -, -(CH 2 ) 4 -, -(CH 2 ) 5 -, -(CH 2 ) 9 -, -(CH 2 ) 10 - or - CH ⁇ -.
  • X is related to a diacylated diamino acid it is preferably N,N ' -dimyristoyi lysine, N,N ' -dilauroyi lysine, or N,N ' -dipalmitoyi lysine, N,N ' -dimyristoyi omithine, N.N ' -dilauroyl ornithine , or N,N ' -dipalmitoyi omithine, or N,N ' - dimyristoyl, N,N ' -dilauroyi, or N,N ' -dipalmitoyi derivatives of other diamino acids listed above.
  • Y is related to an acylated diamino acid it is preferably N ' -myristoyl lysine, N ' -lauroyl lysine, or N '-palmitoyi lysine, N ' - myristoyl ornithine, N ' -lauroyl ornithine , or N ' -palmitoyi ornithine, or N ' - myristoyl, N ' -lauroyl, or N ' -palmitoyi derivatives of other diamino acids listed above.
  • Reagents (reagent grade) were purchased from Merck KGaA unless stated otherwise. Peptides are purified by gel filtration and/or HPLC as needed.
  • SPS high refractive index glass LaSFN9 (Berliner Glas) substrates (2.5*4 * 0.2 cm) by electrothermal evaporation to a thickness of 50 nm.
  • Gold substrates to be used for electrochemical and FTIR measurements are prepared as follows: ELKA microscope glass slides (76 * 22 mm) are cleaned. Subsequently gold is deposited to a layer thickness of 500 nm over a sublayer of 30 nm chromium in a spoon-like pattern to form 8 electrodes per slide. Chromium and gold are deposited by electrothermal evaporation using a Leybold-Heraeus L 650 vapour deposition apparatus at 300 °C and a pressure of 10 -5 bis 10 -6 mbar. Gold substrates are coated with thiopeptide directly after the evaporation process to prevent soiling.
  • Example 1 Preparation of the thiopeptide HS-(CH2)2"CO-Ala-Ser- Ser-Ala-Ala-Ser-Ala-Pro Ser-Ser-OH
  • HS-(CH2)2-CO-Ala-Ser-Ser-Ala-Ala-Ser-Ala-Pro Ser-Ser-OH is obtained by solid phase peptide synthesis in a continuous flow synthesizer using Fmoc (9-fluorenyl-methoxycarbonyl) strategy with acid labile side chain protection on an acid labile Wang-resin. Washes are done with DMA (dimethylaminoacetamide), cleavage of the Fmoc-protection group is achieved with 20% piperidin in DMF.
  • Tritylmercapto- propionic acid is obtained by tritylation of mercatopropionic acid in dichloromethane with excess of triphenylmethanol and TFA catalysis at room temperature.
  • the peptide is removed from the resin and its side chain protection groups are cleaved by treatment with TFA/CH2Cl2/anisol 60/40/1 (20 ml/g resin) for 2-4 h at room temperature.
  • TFA/CH2Cl2/anisol 60/40/1 (20 ml/g resin) for 2-4 h at room temperature.
  • To remove trityl functions 70/20/10 is used instead.
  • the filtrate is concentrated and the peptide precipitated with ether.
  • Example 2 Preparation of the thiopeptide Myr-Lys(Myr)-Ser-Ser-Pro- Ala-Ser-Ser-Ala-Ala-Ser-Ala-Cys-NHz
  • the peptide sequence Ser-Ser-Pro-Ala-Ser-Ser-Ala-Ala-Ser-Ala-Cys-NH 2 is assembled by solid phase peptide synthesis in a continuous flow synthesizer using Fmoc (9-fluorenyl-methoxycarbonyl) strategy with acid labile side chain protection on an acid labile amino xanthenyl resin (obtained from Novabiochem). Ser(But) and Cys(Trt) derivatives are used. Washes are done with DMA (dimethylaminoacetamide), cleavage of the Fmoc-protection group is achieved with 20% piperidin in DMF.
  • Fmoc (9-fluorenyl-methoxycarbonyl) strategy with acid labile side chain protection on an acid labile amino xanthenyl resin (obtained from Novabiochem).
  • Ser(But) and Cys(Trt) derivatives are used. Washes are done with DMA (d
  • the peptide on the resin is modified at the N-terminus with Fmoc-Lys(Fmoc)-OH using the normal coupling procedure.
  • the Fmoc groups are removed again and the capping procedure is used with myristoic acid chloride instead of acetic anhydride to derivatise both amino functions of the N-terminal lysine.
  • the peptide is removed from the resin and its side chain protection groups are cleaved by treatment with TFA/CH2Cl2/anisol 60/40/1 (20 ml/g resin) for 2-4 h at room temperature.
  • TFA/CH2Cl2/anisol 60/40/1 (20 ml/g resin) for 2-4 h at room temperature.
  • TF VCH2Cl2/thiophenol 70/20/10 is used.
  • the filtrate is concentrated and the peptide Myr-Lys(Myr)-Ser-Ser- Pro-Ala-Ser-Ser-Ala-Ala-Ser-Ala-C
  • Example 3 Preparation of the thiopeptide Myr-Om(Myr)-Ala-Ser-Ser- Ala-Ala-Ser-Ala-Pro-Ser-Ser-NH-Et-SH
  • the Fmoc groups are removed again and the capping procedure is used with myristoic acid chloride instead of acetic anhydride to derivatise both amino functions of the N- terminal ornithine.
  • the peptide is removed from the resin and its side chain protection groups are cleaved by treatment with TF VCH2Cl2/thiophenol.
  • the filtrate is concentrated and the peptide Myr-Orn(Myr)-Ser-Ser-Pro-Ala- Ser-Ser-Ala-Ala-Ser-Ala-NH-Et-SH precipitated with ether.
  • Purification is achieved by gel filtration in isopropanol/water 80/20 with 0.05% TFA on Sephadex G10. Purity of the peptides is determined by HPLC, to be usually better than 95%. Identity is found as expected by FAB-MS (fast atom bombardment mass spectroscopy).
  • a gold substrate is incubated for 5 hours in a solution of the thiopeptide (0.4 mg/ml) obtained in Example 1 dissolved in DMF containing 8 mg/ml
  • the gold substrate is rinsed with DMF, water, and ethanol.
  • the slides are dryed under a stream of nitrogen and placed in a solution of 1 mg/ml DMPE (SIGMA) dissolved in a mixture of CHCI 3 and 2-propanol (4:1; v:v) supplemented with 0.25 mg/ml HOBt.
  • SIGMA 1 mg/ml DMPE
  • the terminal carboxy groups of the peptide are activated by reaction with DIC (20 ⁇ l/ml; SIGMA) and coupled by additional incubation with N-ethyl diisopropylamine (10 ⁇ l/ml). Activation and coupling are once more repeated using fresh reagents.
  • the substrate is then rinsed with CHCI 3 , water and dried in a stream of nitrogen.
  • Example 5 Preparation of the thiopeptide bilayer from the thiopeptide lipid adduct The substrates are incubated for 12 h in a solution (0.5 mg/ml) of the thiopeptide lipid (MyrLys(M r)-Ser-Ser-Pro-Ala-Ser-Ala-Ser-Ala-Cys- amide) in TFA, obtained according to Example 2. Subsequently rinsed with TFA, water, and ethanol, and are then dried under a stream of nitrogen.
  • the TFA coating solution of the thiopeptide may also contain thioethanol or the -S-S- dimer of thioacetic acid and/or free phospholipids in order to provide additional hydrophilic groups to accomodate free lipids in the array of covalently bound thiolipids. This is an additional or alternative means with regard to impregnating the teflon spacer with free phospholipid in order to improve the arrangement and fluidity of the thiopeptide supported bilayer.
  • Liposomes are prepared by dialysis from phophatidylcholine from egg yolk (Lipoid E PC; 8 mg/ml), and cholesterol (30%) where indicated.
  • the average diameter of the vesicles is 150 nm. They are expected to be large clearlyamellar vesicles (LUVs), i.e. equilibrated with respect to osmotic pressure.
  • LUVs uniamellar vesicles
  • Substrates prepared as described above are incubated at 30° C overnight in suspensions of the liposomes prepared as described above (0.8 mgl/ml) with the lipid monolayers. Subsequently substrates are rinsed and placed in fresh buffer solution (100 mM K-HEPES, pH7,4, 40 mM KCl, sterilized by filtration).
  • Example 6 Incorporation and activity measurements of the Cytochrome c oxidase from horse heart Cytochrome c oxidase inserts spontaneously into a preformed thiopeptide lipid bilayer, when the protein in the solubilized form (attached to cholate as described by Kadenbach et al. Methods Enzymol. (1986) 126, 32) is diluted below the critical micelle concentration on a lipid bilayer prepared of thiopeptide Myr-Lys(Myr)-Ser-Ser-Pro-Ala-Ser-Ser-Ala-Ala-Ser-Ala-Cys- NH 2 . This process was followed by SPS as shown fig. 4.
  • the thickness of the bilayer increased from about 6nm to 12nm.
  • the activity was monitored by IS.
  • the resistance of the bilayer with cytochrome c oxidase incorporated dropped from 200kOhm to 17kOhm when cytochrome c in a concentration of 8 ⁇ mol/L was added as a substrate. Removal of cytochrome c (by rinsing) or addition of cyanide as inhibitor restored the resistance back to the original value, see fig. 12. Results of single IS measurements are given in Table !
  • the successful incorporation and functional orientation from the incorporated protein was proofed via SPFS.
  • a primary monoclonal antibody against subgroup IV of the cytochrome c oxidase was added to the system, and detected with an secondary polyclonal antibody with a fluorescence label.
  • the resulting fluorescence signal was measured in the SPFS configuration, see fig. 7.
  • Example 7 Incorporation and activity measurements of the acetylcholine receptor (AChR) from Torpedo Californica
  • the AChR was incorporated into the lipid film (prepared from thiopeptide lipid (MyrLys(Myr)-Ser-Ser-Pro-Ala-Ser-Ala-Ser-Ala-Cys-amide) in TFA, obtained according to Example 2) by fusion of liposomes containing the incorporated receptor, fig.5.
  • Preparation of the vesicles 180 mg Av20 + 20mg Cholesterol were diluted in chloroform. The chloroform is removed in an rotary evaporator with subsequent lyophyllisation for 12h. 10ml buffer (500mM NaCl, 10mM HEPES pH 7,4, 2mM CaCI 2 , 0,02% NaN 3 ) are added. After sonification for 1min and 5 frozen/thaw cycles, the vesicles were extruded with an 400nm polycarbonate filter (11 times) frozen with liquid nitrogen and stored under -70°C.
  • 10ml buffer 500mM NaCl, 10mM HEPES pH 7,4, 2mM CaCI 2 , 0,02% NaN 3
  • the vesicles were added to the thiopeptide lipid layer, the fusion process was followed by SPS, see fig.5.
  • the thickness of the monolayer increased from about 4nm to 9nm.
  • the activity was monitored by IS as shown in fjg.13.
  • the resistance dropped from 300kOhm to 10kOhm when acetylcholine in a concentration of 1 ⁇ mol/L was added as a substrate.
  • the successful incorporation and functional orientation from the incorporated protein was proofed via SPFS.
  • a primary monoclonal antibody against the receptor was added to the system, and detected with an secondary polyclonal antibody with a fluorescence label. The resulting fluorescence signal was measured in the SPFS configuration, see fig.7.
  • Example 8 Incorporation and activity measurements of the Na + K + ATPase from shark
  • the ATPase inserts spontaneously into a preformed thiopeptide lipid bilayer, prepared from the thiopeptide lipid (MyrLys(Myr)-Ser-Ser-Pro-Ala- Ser-Ala-Ser-Ala-Cys-amide in TFA, obtained according to Example 2.
  • MyrLys(Myr)-Ser-Ser-Pro-Ala- Ser-Ala-Ser-Ala-Cys-amide in TFA obtained according to Example 2.
  • the protein in the solubilized form is diluted below the critical micelle concentration, (solubilized in E 8 C ⁇ 8 )
  • the activity was monitored by IS, the resistance dropped from 200 kOhm to 20 kOhm, fig.14.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Composite Materials (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Cette invention concerne des membranes cellulaires synthétiques qui sont liées à un support fait d'un métal noble et qui comprennent de nouveaux peptides espaceurs correspondant à la formule (I). Ces membranes peuvent également contenir des protéines de membranes et peuvent être utilisées dans des dispositifs de détection biologique. Cette invention concerne également des peptides ou des composés analogues à des peptides qui correspondent à la formule (I) X - LN - AN - B - AC - LC - Y. Dans un mode de réalisation préféré (a), le groupe X comprend au moins un atome de soufre et représente ainsi, par exemple, un groupe Lip ou un groupe de type HS-(CH¿2?)2-CO-. Les groupes A?N et LN¿ représentent tous deux des liaisons simples, tandis que le groupe AC représente Pro Xaa1 Xaa1. Le groupe LC représente une liaison simple ou un oligomère (ayant un nombre de monomères de 2 à 4) d'un acide aminé φ à chaîne moyenne tel qu'un acide 6-aminocaproïque. Le groupe Y représente quant à lui Lys(Myr)-Lys(Myr), étant entendu que Myr représente un résidu de myristol lié au groupe amino à chaîne latérale de Lys. Dans un autre mode de réalisation préféré (b), le groupe X représente Myr-Lys(Myr), étant entendu que Myr représente des résidus de myristol liés aux groupes amino de Lys. Le groupe LN représente une liaison simple ou un oligomère (ayant un nombre de monomères de 2 à 4) d'un acide aminé φ à chaîne moyenne tel qu'un acide 6-aminocaproïque. Le groupe AN représente Pro Xaa1 Xaa1, tandis que les groupes AC et LC représentent tous deux des liaisons simples. Le groupe Y comprend quant à lui au moins un atome de soufre et représente ainsi, par exemple, un Cys-amide ou un groupe de type -NH-(CH¿2?)2-SH.
PCT/EP1998/006344 1997-10-22 1998-10-06 Peptides espaceurs et membranes contenant ces peptides WO1999020649A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2000516989A JP2001520236A (ja) 1997-10-22 1998-10-06 スペーサーペプチドとそれを含有する膜
EP98954352A EP1025118A1 (fr) 1997-10-22 1998-10-06 Peptides espaceurs et membranes contenant ces peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97118326.4 1997-10-22
EP97118326 1997-10-22

Publications (1)

Publication Number Publication Date
WO1999020649A1 true WO1999020649A1 (fr) 1999-04-29

Family

ID=8227507

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/006344 WO1999020649A1 (fr) 1997-10-22 1998-10-06 Peptides espaceurs et membranes contenant ces peptides

Country Status (3)

Country Link
EP (1) EP1025118A1 (fr)
JP (1) JP2001520236A (fr)
WO (1) WO1999020649A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000070345A1 (fr) * 1999-05-14 2000-11-23 Iris Bio Technologies Immobilisation reversible de ligands sur des surfaces metalliques, leur preparation et leur utilisation dans des applications biochimiques
DE10157070A1 (de) * 2001-11-16 2003-06-05 Univ Dresden Tech Anordnung zur Messung von durch Ionenkanäle fließende Ionenströme, sowie Verfahren zur Herstellung dieser und Messverfahren
WO2003052420A3 (fr) * 2001-10-03 2003-10-30 Purdue Res Foundatio Dispositif et procedes utilisant une membrane biofonctionnalisee asymetrique
WO2004042060A1 (fr) * 2002-11-08 2004-05-21 University Of Copenhagen Procede permettant d'immobiliser une proteine sur une zeolithe
WO2005067978A3 (fr) * 2004-01-17 2006-08-24 Univ Manchester Systeme de transport de medicaments
EP2281194A1 (fr) * 2008-04-24 2011-02-09 Svanova Biotech Ab Ensemble moléculaire comprenant de l'or et un liant pour la détection d'entités biochimiques
EP2726870A4 (fr) * 2011-06-29 2015-03-11 Academia Sinica Capture, purification et libération d'une substance biologique utilisant un revêtement de surface
US20160100778A1 (en) * 2014-10-10 2016-04-14 Korea Institute Of Science And Technology Biosensor and wearable device for detecting bioinformation including hybrid electronic sheet
CN106380430A (zh) * 2016-09-05 2017-02-08 吉尔生化（上海）有限公司 一种3‑(三苯甲硫基)丙酸的合成方法
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
US10112198B2 (en) 2014-08-26 2018-10-30 Academia Sinica Collector architecture layout design
US10495644B2 (en) 2014-04-01 2019-12-03 Academia Sinica Methods and systems for cancer diagnosis and prognosis
US10568579B2 (en) 2015-04-02 2020-02-25 Korea Institute Of Science And Technology Pressure sensor including hybrid electronic sheet and wearable device including the pressure sensor

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105860960B (zh) * 2016-04-20 2018-04-03 河南大学 一种基于金纳米颗粒的细胞膜荧光探针及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005305A1 (fr) * 1988-11-10 1990-05-17 Pharmacia Ab Ensemble capteur a resonance de plasmon de surface et son utilisation dans des systemes de biocapteurs
EP0441120A2 (fr) * 1990-01-09 1991-08-14 Yeda Research And Development Co. Ltd. Biosenseurs
WO1996018645A1 (fr) * 1994-12-16 1996-06-20 Merck Patent Gmbh Peptides et membranes cellulaires synthetiques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005305A1 (fr) * 1988-11-10 1990-05-17 Pharmacia Ab Ensemble capteur a resonance de plasmon de surface et son utilisation dans des systemes de biocapteurs
EP0441120A2 (fr) * 1990-01-09 1991-08-14 Yeda Research And Development Co. Ltd. Biosenseurs
WO1996018645A1 (fr) * 1994-12-16 1996-06-20 Merck Patent Gmbh Peptides et membranes cellulaires synthetiques

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D. J VD HEUVEL ET AL: "Synthetic peptides as receptors in affinity sensors: a feasibility study", ANALYTICAL BIOCHEMISTRY, vol. 215, 1993, pages 223 - 230, XP002097192 *
N. BUNJES ET AL.: "Thiopeptide-supported lipid layers on solid surfaces", LANGMUIR, vol. 13, November 1997 (1997-11-01), pages 6188 - 6194, XP002097603 *
R. NAUMANN ET AL.: "Incorporation of membrane proteins in solid-supported lipid layers", ANGEWANDTE CHEMIE. INTERNATIONAL EDITION., vol. 34, no. 18, 1995, WEINHEIM DE, pages 2056 - 2058, XP002097604 *
T. KELLER ET AL: "Reversible oriented immobilization of histidine-tagged proteins on gold surfaces using a chelator thioalkane", SUPRAMOLECULAR SCIENCE, vol. 2, no. 3/04, 1995, pages 155 - 160, XP002082734 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000070345A1 (fr) * 1999-05-14 2000-11-23 Iris Bio Technologies Immobilisation reversible de ligands sur des surfaces metalliques, leur preparation et leur utilisation dans des applications biochimiques
US7108971B2 (en) 1999-05-14 2006-09-19 Iris Biotechnologies, Inc. Reversible binding of molecules to metal substrates through affinity interactions
US7374944B2 (en) 2001-10-03 2008-05-20 Purdue Research Foundation Device and bioanalytical method utilizing asymmetric biofunctionalized membrane
WO2003052420A3 (fr) * 2001-10-03 2003-10-30 Purdue Res Foundatio Dispositif et procedes utilisant une membrane biofonctionnalisee asymetrique
DE10157070A1 (de) * 2001-11-16 2003-06-05 Univ Dresden Tech Anordnung zur Messung von durch Ionenkanäle fließende Ionenströme, sowie Verfahren zur Herstellung dieser und Messverfahren
DE10157070B4 (de) * 2001-11-16 2005-11-17 Technische Universität Dresden Anordnung zur Messung von durch Ionenkanäle fließenden Ionenströmen, sowie Verfahren zur Herstellung dieser und Messverfahren
WO2004042060A1 (fr) * 2002-11-08 2004-05-21 University Of Copenhagen Procede permettant d'immobiliser une proteine sur une zeolithe
US8772248B2 (en) 2004-01-17 2014-07-08 Keele University Drug delivery system
WO2005067978A3 (fr) * 2004-01-17 2006-08-24 Univ Manchester Systeme de transport de medicaments
EP2281194A1 (fr) * 2008-04-24 2011-02-09 Svanova Biotech Ab Ensemble moléculaire comprenant de l'or et un liant pour la détection d'entités biochimiques
EP2281194A4 (fr) * 2008-04-24 2011-05-18 Svanova Biotech Ab Ensemble moléculaire comprenant de l'or et un liant pour la détection d'entités biochimiques
EP2726870A4 (fr) * 2011-06-29 2015-03-11 Academia Sinica Capture, purification et libération d'une substance biologique utilisant un revêtement de surface
US11674958B2 (en) 2011-06-29 2023-06-13 Academia Sinica Capture, purification, and release of biological substances using a surface coating
US9541480B2 (en) 2011-06-29 2017-01-10 Academia Sinica Capture, purification, and release of biological substances using a surface coating
US10495644B2 (en) 2014-04-01 2019-12-03 Academia Sinica Methods and systems for cancer diagnosis and prognosis
US10112198B2 (en) 2014-08-26 2018-10-30 Academia Sinica Collector architecture layout design
US20160100778A1 (en) * 2014-10-10 2016-04-14 Korea Institute Of Science And Technology Biosensor and wearable device for detecting bioinformation including hybrid electronic sheet
US10568579B2 (en) 2015-04-02 2020-02-25 Korea Institute Of Science And Technology Pressure sensor including hybrid electronic sheet and wearable device including the pressure sensor
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
US10605708B2 (en) 2016-03-16 2020-03-31 Cellmax, Ltd Collection of suspended cells using a transferable membrane
CN106380430A (zh) * 2016-09-05 2017-02-08 吉尔生化（上海）有限公司 一种3‑(三苯甲硫基)丙酸的合成方法

Also Published As

Publication number Publication date
JP2001520236A (ja) 2001-10-30
EP1025118A1 (fr) 2000-08-09

Similar Documents

Publication Publication Date Title
Heyse et al. Emerging techniques for investigating molecular interactions at lipid membranes
Naumann et al. Proton transport through a peptide-tethered bilayer lipid membrane by the H+-ATP synthase from chloroplasts measured by impedance spectroscopy
EP1025118A1 (fr) Peptides espaceurs et membranes contenant ces peptides
Gazit et al. The Assembly and Organization of the α5 and α7 Helices from the Pore-forming Domain of Bacillusthuringiensis δ-Endotoxin: RELEVANCE TO A FUNCTIONAL MODEL
US20070224639A1 (en) Substrate for immobilizing biomolecules, biochip, and biosensor
Stora et al. Histidine-tagged amphiphiles for the reversible formation of lipid bilayer aggregates on chelator-functionalized gold surfaces
US8759008B2 (en) Robust, self-assembled, biocompatible films
Silvestro et al. Infrared spectroscopy of supported lipid monolayer, bilayer, and multibilayer membranes
ES2271253T3 (es) Biosensor con proteinas transmembrana unidas covalentemente.
Algar et al. Synthesizing and modifying peptides for chemoselective ligation and assembly into quantum dot-peptide bioconjugates
AU2005258899A1 (en) Annexins, derivatives thereof, and Annexin-Cys variants, as well as therapeutic and diagnostic uses thereof
US5962638A (en) Peptides and synthetic cell membranes
EP2984102B1 (fr) Cages peptidiques autoassemblantes préparés à partir de modules peptidiques bispirales
Uvdal et al. Chemisorption of the dipeptide Arg-Cys on a gold surface and the selectivity of G-protein adsorption
Andersson et al. Solid-supported lipid bilayers–A versatile tool for the structural and functional characterization of membrane proteins
Baumgart et al. Fusion of small unilamellar vesicles onto laterally mixed self-assembled monolayers of thiolipopeptides
Keller et al. Reversible oriented immobilization of histidine-tagged proteins on gold surfaces using a chelator thioalkane
Liu et al. Specific binding of avidin to biotin containing lipid lamella surfaces studied with monolayers and liposomes
EP2746772B1 (fr) Particules enveloppées de membrane lipidique avec des protéines de membrane
JP2011185874A (ja) 生体分子分析用キット、これを用いた生体分子の分析方法
Jelinek et al. Biomimetic approaches for studying membrane processes
JP2003156497A (ja) 新規支持膜、その調製及び使用
Schuy et al. In situ Synthesis of Lipopeptides as Versatile Receptors for the Specific Binding of Nanoparticles and Liposomes to Solid‐Supported Membranes
Schiller et al. Self-assembled tethered bimolecular lipid membranes
Busch et al. Single molecule research on surfaces: from analytics to construction and back

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1998954352

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09529960

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998954352

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998954352

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载